12/15-lipoxygenase-dependent myeloid production of interleukin-12 is essential for resistance to chronic toxoplasmosis

Infection and Immunity

Volumn 77, Issue 12, 2009, Pages 5690-5700

  Middleton, Melissa K ^a   Zukas, Alicia M ^a   Rubinstein, Tanya ^a   Kinder, Michelle ^a   Wilson, Emma H ^a   Zhu, Peijuan ^a   Blair, Ian A ^a   Hunter, Christopher A ^a   Puré, Ellen ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 15 LIPOXYGENASE; GAMMA INTERFERON; INTERLEUKIN 12; LIPOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CHRONIC DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENCEPHALITIS; IMMUNE RESPONSE; INFECTION RESISTANCE; INFECTION SENSITIVITY; INFLAMMATION; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SPLEEN CELL; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ANIMALS; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; BODY WEIGHT; BRAIN; CELLS, CULTURED; FEMALE; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-12; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, INBRED C57BL; SPLEEN; SURVIVAL ANALYSIS; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL;

EID: 72449156038     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00560-09     Document Type: Article

References (58)

1. Aikawa, M., and P. Libby. 2004. Atherosclerotic plaque inflammation: the final frontier? Can. J. Cardiol. 20:631-634. (Pubitemid 38811583)
2. Aliberti, J., S. Hieny, C. Reis e Sousa, C. N. Serhan, and A. Sher. 2002. Lipoxin-mediated inhibition of IL-12 production by DCs: a mechanism for regulation of microbial immunity. Nat. Immunol. 3:76-82.
3. 4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J. Exp. Med. 196:1253-1262.
4. Aliberti, J., and A. Sher. 2002. Positive and negative regulation of pathogen induced dendritic cell function by G-protein coupled receptors. Mol. Immunol. 38:891-893.
5. Blass, S. L., E. Pure, and C. A. Hunter. 2001. A role for CD44 in the production of IFN-gamma and immunopathology during infection with Toxoplasma gondii. J. Immunol. 166:5726-5732. (Pubitemid 32374198)
6. Bocan, T. M., W. S. Rosebury, S. B. Mueller, S. Kuchera, K. Welch, A. Daugherty, and J. A. Cornicelli. 1998. A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia- induced atherosclerosis in the rabbit. Atherosclerosis 136:203-216.
7. Brys, L., A. Beschin, G. Raes, G. H. Ghassabeh, W. Noel, J. Brandt, F. Brombacher, and P. De Baetselier. 2005. Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J. Immunol. 174:6095-6104.
8. Chinnici, C. M., Y. Yao, T. Ding, C. D. Funk, and D. Pratico. 2005. Absence of 12/15 lipoxygenase reduces brain oxidative stress in apolipoprotein E-deficient mice. Am. J. Pathol. 167:1371-1377.
9. Conrad, D. J. 1999. The arachidonate 12/15 lipoxygenases. A review of tissue expression and biologic function. Clin. Rev. Allergy Immunol. 17:71-89.
10. Gabaglia, C. R., E. E. Sercarz, Y. Diaz-De-Durana, M. Hitt, F. L. Graham, J. Gauldie, and T. A. Braciak. 2004. Life-long systemic protection in mice vaccinated with L. major and adenovirus IL-12 vector requires active infection, macrophages and intact lymph nodes. Vaccine 23:247-257.
11. Gazzinelli, R. T., M. Wysocka, S. Hayashi, E. Y. Denkers, S. Hieny, P. Caspar, G. Trinchieri, and A. Sher. 1994. Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with Toxoplasma gondii. J. Immunol. 153:2533-2543.
12. Hedi, H., and G. Norbert. 2004. 5-Lipoxygenase pathway, dendritic cells, and adaptive immunity J. Biomed. Biotechnol. 2004:99-105.
13. Hodge-Dufour, J., P. W. Noble, M. R. Horton, C. Bao, M. Wysoka, M. D. Burdick, R. M. Strieter, G. Trinchieri, and E. Pure. 1997. Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages. J. Immunol. 159:2492-2500.
14. Holtschke, T., J. Lohler, Y. Kanno, T. Fehr, N. Giese, F. Rosenbauer, J. Lou, K. P. Knobeloch, L. Gabriele, J. F. Waring, M. F. Bachmann, R. M. Zinkernagel, H. C. Morse III, K. Ozato, and I. Horak. 1996. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87:307-317.
15. Kaufmann, S. H. 1991. The macrophage in tuberculosis: sinner or saint? The T cell decides. Pathobiology 59:153-155.
16. Kim, Y. S., M. A. Reddy, L. Lanting, S. G. Adler, and R. Natarajan. 2003. Differential behavior of mesangial cells derived from 12/15-lipoxygenase knockout mice relative to control mice. Kidney Int. 64:1702-1714.
17. Lang, C., U. Gross, and C. G. Luder. 2007. Subversion of innate and adaptive immune responses by Toxoplasma gondii. Parasitol. Res. 100:191-203.
18. Lawrence, T., M. Bebien, G. Y. Liu, V. Nizet, and M. Karin. 2005. IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation. Nature 434:1138-1143. (Pubitemid 40663493)
19. Leemans, J. C., T. Thepen, S. Weijer, S. Florquin, N. van Rooijen, J. G. van de Winkel, and T. van der Poll. 2005. Macrophages play a dual role during pulmonary tuberculosis in mice. J. Infect. Dis. 191:65-74.
20. Levitz, S. M., and R. D. Diamond. 1985. A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT. J. Infect. Dis. 152:938-945.
21. Li, S. L., R. S. Dwarakanath, Q. Cai, L. Lanting, and R. Natarajan. 2005. Effects of silencing leukocyte-type 12/15-lipoxygenase using short interfering RNAs. J. Lipid Res. 46:220-229. (Pubitemid 40271085)
22. Lieberman, L. A., F. Cardillo, A. M. Owyang, D. M. Rennick, D. J. Cua, R. A. Kastelein, and C. A. Hunter. 2004. IL-23 provides a limited mechanism of resistance to acute toxoplasmosis in the absence of IL-12. J. Immunol. 173:1887-1893.
23. Liu, B., L. J. Marnett, A. Chaudhary, C. Ji, I. A. Blair, C. R. Johnson, C. A. Diglio, and K. V. Honn. 1994. Biosynthesis of 12(S)- hydroxyeicosatetraenoic acid by B16 amelanotic melanoma cells is a determinant of their metastatic potential. Lab. Investig. 70:314-323.
24. Locksley, R. M., J. Fankhauser, and W. R. Henderson. 1985. Alteration of leukotriene release by macrophages ingesting Toxoplasma gondii. Proc. Natl. Acad. Sci. USA 82:6922-6926.
25. Mahida, Y. R. 2000. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm. Bowel Dis. 6:21-33.
26. Makheja, A. N. 1992. Atherosclerosis: the eicosanoid connection. Mol. Cell. Biochem. 111:137-142.
27. Middleton, M. K., T. Rubinstein, and E. Puré. 2006. Cellular and molecular mechanisms of the selective regulation of IL-12 production by 12/15-lipoxygenase. J. Immunol. 176:265-274. (Pubitemid 43023271)
28. Middleton, M. K., A. M. Zukas, T. Rubinstein, M. Jacob, P. Zhu, L. Zhao, I. Blair, and E. Puré. 2006. Identification of 12/15-lipoxygenase as a suppressor of myeloproliferative disease. J. Exp. Med. 203:2529-2540.
29. Montoya, J. G., and O. Liesenfeld. 2004. Toxoplasmosis. Lancet 363:1965-1976.
30. Morgan, A. H., V. Dioszeghy, B. H. Maskrey, C. P. Thomas, S. R. Clark, S. A. Mathie, C. M. Lloyd, H. Kühn, N. Topley, B. C. Coles, P. R. Taylor, S. A. Jones, and V. B. O'Donnell. 2009. Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation-dependent formation in Th-2 disease. J. Biol. Chem. 284:21185-21191.
31. Natarajan, R., and J. L. Nadler. 2003. Lipoxygenases and lipid signaling in vascular cells in diabetes. Front. Biosci. 8:s783-s795.
32. Rankin, S. M., S. Parthasarathy, and D. Steinberg. 1991. Evidence for a dominant role of lipoxygenase(s) in the oxidation of LDL by mouse peritoneal macrophages. J. Lipid Res. 32:449-456.
33. Reddy, M. A., Y. S. Kim, L. Lanting, and R. Natarajan. 2003. Reduced growth factor responses in vascular smooth muscle cells derived from 12/15-lipoxygenase-deficient mice. Hypertension 41:1294-1300. (Pubitemid 36706080)
34. Reichmann, G., W. Walker, E. N. Villegas, L. Craig, G. Cai, J. Alexander, and C. A. Hunter. 2000. The CD40/CD40 ligand interaction is required for resistance to toxoplasmic encephalitis. Infect. Immun. 68:1312-1318.
35. Reilly, K. B., S. Srinivasan, M. E. Hatley, M. K. Patricia, J. Lannigan, D. T. Bolick, G. Vandenhoff, H. Pei, R. Natarajan, J. L. Nadler, and C. C. Hedrick. 2004. 12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo. J. Biol. Chem. 279:9440-9450.
36. Reis e Sousa, C., S. Hieny, T. Scharton-Kersten, D. Jankovic, H. Charest, R. N. Germain, and A. Sher. 1997. In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J. Exp. Med. 186:1819-1829.
37. Rocha, P. N., T. J. Plumb, and T. M. Coffman. 2003. Eicosanoids: lipid mediators of inflammation in transplantation. Springer Semin. Immunopathol. 25:215-227.
38. Russell, T. D., Q. Yan, G. Fan, A. P. Khalifah, D. K. Bishop, S. L. Brody, and M. J. Walter. 2003. IL-12 p40 homodimer-dependent macrophage chemotaxis and respiratory viral inflammation are mediated through IL-12 receptor beta 1. J. Immunol. 171:6866-6874.
39. Scanga, C. A., J. Aliberti, D. Jankovic, F. Tilloy, S. Bennouna, E. Y. Denkers, R. Medzhitov, and A. Sher. 2002. Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J. Immunol. 168:5997-6001.
40. Scharton-Kersten, T., C. Contursi, A. Masumi, A. Sher, and K. Ozato. 1997. Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction. J. Exp. Med. 186:1523-1534.
41. Scharton-Kersten, T. M., T. A. Wynn, E. Y. Denkers, S. Bala, E. Grunvald, S. Hieny, R. T. Gazzinelli, and A. Sher. 1996. In the absence of endogenous IFN-gamma, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection. J. Immunol. 157:4045-4054.
42. Scharton-Kersten, T. M., G. Yap, J. Magram, and A. Sher. 1997. Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen Toxoplasma gondii. J. Exp. Med. 185:1261-1273.
43. Schluter, D., T. Meyer, L. Y. Kwok, M. Montesinos-Rongen, S. Lutjen, A. Strack, M. L. Schmitz, and M. Deckert. 2002. Phenotype and regulation of persistent intracerebral T cells in murine Toxoplasma encephalitis. J. Immunol. 169:315-322.
44. Seder, R. A., B. L. Kelsall, and D. Jankovic. 1996. Differential roles for IL-12 in the maintenance of immune responses in infectious versus autoimmune disease. J. Immunol. 157:2745-2748.
45. Serhan, C. N., M. Hamberg, and B. Samuelsson. 1984. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. USA 81:5335-5339.
46. Son, Y. I., S. Egawa, T. Tatsumi, R. E. Redlinger, Jr., P. Kalinski, and T. Kanto. 2002. A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. J. Immunol. Methods 262:145-157.
47. Spanbroek, R., M. Hildner, A. Kohler, A. Muller, F. Zintl, H. Kuhn, O. Radmark, B. Samuelsson, and A. J. Habenicht. 2001. IL-4 determines eicosanoid formation in dendritic cells by down-regulation of 5-lipoxygenase and up-regulation of 15-lipoxygenase 1 expression. Proc. Natl. Acad. Sci. USA 98:5152-5157.
48. Subauste, C. S., and J. S. Remington. 1993. Immunity to Toxoplasma gondii. Curr. Opin. Immunol. 5:532-537.
49. Sun, D., and C. D. Funk. 1996. Disruption of 12/15-lipoxygenase expression in peritoneal macrophages. Enhanced utilization of the 5-lipoxygenase pathway and diminished oxidation of low density lipoprotein. J. Biol. Chem. 271:24055-24062.
50. Suzuki, Y., F. K. Conley, and J. S. Remington. 1989. Importance of endogenous IFN-gamma for prevention of toxoplasmic encephalitis in mice. J. Immunol. 143:2045-2050. (Pubitemid 19241227)
51. Suzuki, Y., M. A. Orellana, S. Y. Wong, F. K. Conley, and J. S. Remington. 1993. Susceptibility to chronic infection with Toxoplasma gondii does not correlate with susceptibility to acute infection in mice. Infect. Immun. 61:2284-2288.
52. Thardin, J. F., C. M'Rini, M. Beraud, J. Vandaele, M. F. Frisach, M. H. Bessieres, J. P. Seguela, and B. Pipy. 1993. Eicosanoid production by mouse peritoneal macrophages during Toxoplasma gondii penetration: role of parasite and host cell phospholipases. Infect. Immun. 61:1432-1441.
53. Tsujimura, H., T. Tamura, C. Gongora, J. Aliberti, C. Reis e Sousa, A. Sher, and K. Ozato. 2003. ICSBP/IRF-8 retrovirus transduction rescues dendritic cell development in vitro. Blood 101:961-969.
54. Wei, C., P. Zhu, S. J. Shah, and I. A. Blair. 2009. 15-oxo- Eicosatetraenoic acid, a metabolite of macrophage 15-hydroxyprostaglandin dehydrogenase that inhibits endothelial cell proliferation. Mol. Pharmacol. 76:516-525.
55. Wilson, E. H., U. Wille-Reece, F. Dzierszinski, and C. A. Hunter. 2005. A critical role for IL-10 in limiting inflammation during toxoplasmic encephalitis. J. Neuroimmunol. 165:63-74.
56. Yang, X. Y., L. H. Wang, K. Mihalic, W. Xiao, T. Chen, P. Li, L. M. Wahl, and W. L. Farrar. 2002. Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor gamma activated by macrophage-derived 12/15-lipoxygenase ligands. J. Biol. Chem. 277:3973-3978.
57. Yap, G., M. Pesin, and A. Sher. 2000. Cutting edge: IL-12 is required for the maintenance of IFN-gamma production in T cells mediating chronic resistance to the intracellular pathogen, Toxoplasma gondii. J. Immunol. 165:628-631. (Pubitemid 30484726)
58. Zhao, L., C. A. Cuff, E. Moss, U. Wille, T. Cyrus, E. A. Klein, D. Pratico, D. J. Rader, C. A. Hunter, E. Puré, and C. D. Funk. 2002. Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J. Biol. Chem. 277:35350-35356.